Advertisement

/PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the thirteen abstracts relating to its proprietary diagnostic platform presented at Digestive Disease Week (DDW) 2012.

The abstracts highlight Prometheus's innovative technologies aimed at helping healthcare providers personalize patient care with the goal of ultimately helping to improve patient outcomes.

Topics span across a wide spectrum of scientific and clinical research that offers novel solutions to current and future patient needs. "We are proud to continue to lead the way toward personalized medicine. We are committed to continue to advance our novel technology platforms and partner with the GI community to help bring valuable products to market with the goal of continuing to improve patient outcomes," said Joseph M. Limber, President and Chief Executive Officer of Prometheus.

In the Feagan et al abstract, antibody-to-infliximab (ATI) levels proved highly predictive of disease activity, as measured by median C-reactive protein (CRP) concentrations - regardless of serum infliximab (IFX) levels. Both ATI and IFX levels were measured using the novel Prometheus mobility shift assay among more than 1,487 samples from 532 participants in four prospective Crohn's disease randomized controlled trials. CRP concentrations were higher among ATI positive patients with IFX levels < 3 ug/ml (8.4 vs. 5.65; p 0.001) as well as IFX levels > 3 ug/ml (9.9 vs. 1.5; p < 0.01), as compared to ATI negative patients.

The development of these antibodies can shorten the duration of clinical response to IFX and decrease the likelihood of an IBD patient remaining in remission.

"Knowing exactly what factors contribute to a patient's loss of response to a biologic therapy is ideal for accurately and efficiently determining an appropriate course of action to restore treatment response," said Brian Feagan, M.D., Director, Robarts Clinical Trials, Robarts Research Institute. "Our data suggest that antibodies-to-infliximab are highly predictive of disease activity and may help establish a new standard of care that includes combined IFX-ATI monitoring for IBD patients treated with biologics."

Oral presentations:

-- Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD), presentation #565 in Research Forum by Brian G. Feagan et al on May 20 (4:30-4:45 p.m. PDT)

-- Antibodies to infliximab can either be persistent or transient: a retrospective case-control study in IBD patients treated with infliximab maintenance therapy, presentation #563 in Research Forum by Niels Vande Casteele et al on May 20 (4:00-4:15 p.m. PDT)

-- Combined serologic, genetic, and inflammatory markers can accurately differentiate non-IBD, Crohn's disease, and ulcerative colitis patients, presentation #166 in Research Forum by Scott E. Plevy et al on May 19 (3:30-3:45 p.m. PDT)

-- Blood microRNA (miRNA) Expression Patterns Can Identify Inflammatory Bowel Disease (IBD) Patients with Dysplasia and Cancer, presentation #108 in Research Forum by Francis A. Farraye et al on May 19 (10:30-10:45 a.m. PDT)

Poster presentations:

-- New assay to detect infliximab levels and anti-infliximab antibodies from a single serum sample is useful in measuring efficacy of treatment with infliximab in children with IBD (#Sa2037), May 19

-- Accelerated clearance of serum infliximab therapy for acute ulcerative colitis is associated with treatment failure (#Sa2031), May 19

-- Association of serum infliximab and antibodies to infliximab to long term clinical outcome in acute ulcerative colitis (#Sa2047), May 19

-- Comparison of homogeneous mobility shift assay and solid phase ELISA for the measurement of drug and anti-drug antibody (ADA) levels in serum from patients treated with anti-TNF biologics (#Su1928), May 20

-- Alosetron treatment reduced health care utilization and improved symptoms more effectively than traditional therapy in women with severe IBS-D (#Tu1386), May 22

-- Real-world use of alosetron: results of a multi-center observational study (#Tu1393), May 22

-- Evaluation of phosphorylation signatures in suspected pancreatic cancer using endoscopic ultrasound-guided fine needle (EUS-FNA) aspirates: a feasibility study (#Su1909), May 20

-- Comparison of phosphorylation signatures in patients with suspected pancreatic cancer undergoing endoscopic ultrasound-fine needle (EUS-FNA) with and without malignant cytology: a pilot study (#Sa1520), May 19

-- Psychological variables add incremental value to biological markers in differentiating IBS from healthy volunteers (#Tu1392), May 22

Advertisement
Advertisement